Italia markets closed

Sana Biotechnology, Inc. (SANA)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
10,000,00 (0,00%)
Alla chiusura: 04:00PM EDT
10,23 +0,23 (+2,30%)
Dopo ore: 07:56PM EDT

Sana Biotechnology, Inc.

188 East Blaine Street
Suite 400
Seattle, WA 98102
United States
206 701 7914
https://www.sana.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno328

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Steven D. Harr M.D.President, CEO & Director1,04MN/D1970
Mr. Bernard J. Cassidy J.D.Executive VP, General Counsel & Corporate Secretary491,39kN/D1955
Mr. Nathan Hardy M.B.A.Executive VP & CFO683,49kN/D1976
Dr. Edward Rebar Ph.D.Senior VP & CTON/DN/D1968
Ms. Robin AndrulevichExecutive VP & Chief People OfficerN/DN/D1966
Mr. Paul Brunetta M.D.Senior VP and Head of Clinical & Translational ScienceN/DN/DN/D
Mr. Christian Hordo M.B.A.Executive VP & Chief Business Officer485,03kN/D1983
Dr. Sonja Schrepfer M.D., Ph.D.Senior VP & Head of Hypoimmune PlatformN/DN/D1975
Dr. Terry Fry M.D.Senior VP & Head of T Cell TherapeuticsN/DN/D1967
Dr. Steven A. Goldman M.D., Ph.D.Senior VP & Head of CNS TherapyN/DN/D1958
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Governance aziendale

L'ISS Governance QualityScore di Sana Biotechnology, Inc. al 1 marzo 2024 è 8. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 6; diritti degli azionisti: 8; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.